Solid Biosciences
SLDB
36 hedge funds and large institutions have $40.7M invested in Solid Biosciences in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 3 closing their positions.
0% more funds holding
Funds holding: 36 → 36 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
2.76% less ownership
Funds ownership: 83.37% → 80.61% (-2.8%)
13% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 8
52% less capital invested
Capital invested by funds: $85.6M → $40.7M (-$44.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$51.4K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$38.8K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.83K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.77K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$5.48K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$520K |
| 2 |
CCM
CAAS Capital Management
New York
|
-$146K |
| 3 |
CIBC Asset Management
Toronto,
Ontario, Canada
|
-$63.3K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$27.4K |
| 5 |
BlackRock
New York
|
-$26.2K |
SLDB Hedge Fund Activity: Q3 2023 in Review
36 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Solid Biosciences (SLDB) for Q3 2023, worth a combined $40.7M — down 52% from $85.6M a quarter earlier.
Fund positioning in SLDB was balanced in Q3 2023: 3 funds opened new positions, 3 closed out, 7 added to existing stakes and 8 trimmed.
The largest buyer was Geode Capital Management, adding an estimated $51.4K. The largest seller was Great Point Partners, cutting an estimated $520K.
- 36 institutional investors held Solid Biosciences (SLDB) as of Q3 2023, unchanged from Q2 2023.
- Funds reported $40.7M of Solid Biosciences stock for Q3 2023, down 52% quarter-over-quarter.
- 3 funds opened new Solid Biosciences positions in Q3 2023 and 3 closed out, a net change of 0 holders.
- The largest Solid Biosciences buyer in Q3 2023 was Geode Capital Management, an estimated $51.4K added.
- The largest Solid Biosciences seller in Q3 2023 was Great Point Partners, an estimated $520K sold.
Based on aggregated 13F filings for Q3 2023.